Intermittent fasting versus continuous energy restriction in MASLD: a systematic review and meta-analysis
Li H, Li T
Frontiers in nutrition · 0 citas
Cómo se estudió
- Diseño
- Revisión sistemática (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
Según la declaración de financiación del texto completo.
Publicación
- Publicado
- 2026-05-13 · Front Nutr · vol. 13 · pág. 1833688
- Editorial
- Frontiers Media
- Citado
- 0 citas · más que el 23% de estudios similares · 0.0× el promedio de su campo
- Referencias
- 47 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY
- Áreas de investigación
- Dietary Effects on Health · Liver Disease Diagnosis and Treatment · Diet, Metabolism, and Disease
- Palabras clave
- intermittent fasting, continuous energy restriction, non-alcoholic fatty liver disease, hepatic steatosis, controlled attenuation parameter, LDL cholesterol, weight loss, dietary intervention
2 autores
- Hanlu Li🇨🇳Chongqing Medical University
- Tianju Li🇨🇳 · autor de correspondenciaChongqing Medical University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Intermittent fasting (IF) and continuous energy restriction (CER) are widely used dietary approaches for metabolic dysfunction-associated steatotic liver disease (MASLD), yet their comparative efficacy remains uncertain.
Methods
PubMed, Embase, Web of Science, and Cochrane Central were searched from inception to August 1, 2025, for randomized controlled trials comparing intermittent fasting (IF) with continuous energy restriction (CER) in adults with NAFLD, MAFLD, or MASLD. Risk of bias was assessed using RoB 2, and weighted mean differences were pooled using random-effects models.
Results
Nine trials (n = 894) were included, involving time-restricted feeding (TRF), alternate-day fasting (ADF), and 5:2 fasting (whole-day fasting, WDF). Compared with CER, IF was associated with greater reductions in body weight (MD = -1.29 kg; 95% CI, -1.98 to -0.61), BMI (MD = -0.34 kg/m2; 95% CI, -0.55 to -0.13), LDL-C (MD = -0.08 mmol/L; 95% CI, -0.15 to -0.01), and controlled attenuation parameter (CAP) (MD = -15.13 dB/m; 95% CI, -28.87 to -1.39). No significant between-group differences were observed for magnetic resonance imaging-proton density fat fraction (MRI-PDFF), liver stiffness, transaminases, glucose-related indices, total cholesterol, triglycerides, or HDL-C. In subgroup analyses, WDF was associated with a greater reduction in CAP, whereas TRF appeared to be associated with greater reductions in body weight and BMI.
Conclusion
In patients with MASLD, intermittent fasting was associated with greater reductions in body weight, BMI, and LDL-C than continuous energy restriction. Although CAP-based analyses suggested a possible advantage of intermittent fasting for hepatic steatosis, this finding was not confirmed by MRI-PDFF and was no longer statistically significant in sensitivity analyses. Further large-scale, long-term randomized trials are needed to confirm these findings.
Systematic review registration
https://www.crd.york.ac.uk/PROSPERO/view/CRD420251149184, Identifier: CRD420251149184.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.